Carrascosa-Saez M, Colom-Rodrigo A, Gonzalez-Martinez I, Perez-Gomez R, Garcia-Rey A, Piqueras-Losilla D
    
    
    Lab Anim (NY). 2025; .
  
  
    PMID: 40016516
    
    
          DOI: 10.1038/s41684-025-01506-7.
      
 
                                  
  
    Zhou H, Xu J, Pan L
    
    
    Cell Commun Signal. 2025; 23(1):97.
  
  
    PMID: 39966885
    
          PMC: 11837677.
    
          DOI: 10.1186/s12964-025-02102-5.
      
 
                                  
  
    Taghavi A, Springer N, Zanon P, Li Y, Li C, Childs-Disney J
    
    
    RSC Chem Biol. 2025; .
  
  
    PMID: 39957993
    
          PMC: 11824871.
    
          DOI: 10.1039/d4cb00272e.
      
 
                                  
  
    Provenzano M, Ikegami K, Bates K, Gaynor A, Hartman J, Jones A
    
    
    J Clin Invest. 2025; 135(4).
  
  
    PMID: 39836447
    
          PMC: 11827844.
    
          DOI: 10.1172/JCI185426.
      
 
                                  
  
    Ocampo-Ortega S, Sierra-Sanchez V, Blancas-Napoles C, Gonzalez-Carteno A, Mera-Jimenez E, Macias-Perez M
    
    
    Life (Basel). 2025; 14(12.
  
  
    PMID: 39768315
    
          PMC: 11677511.
    
          DOI: 10.3390/life14121607.
      
 
                              
              
                              
                                      
  A cyclic pyrrole-imidazole polyamide reduces pathogenic RNA in CAG/CTG triplet repeat neurological disease models.
  
    Ikenoshita S, Matsuo K, Yabuki Y, Kawakubo K, Asamitsu S, Hori K
    
    
    J Clin Invest. 2023; 133(22).
  
  
    PMID: 37707954
    
          PMC: 10645379.
    
          DOI: 10.1172/JCI164792.
      
 
                                          
                                                          
  Promising AAV.U7snRNAs vectors targeting  improve DM1 hallmarks in patient-derived cell lines.
  
    Almeida C, Robriquet F, Vetter T, Huang N, Neinast R, Hernandez-Rosario L
    
    
    Front Cell Dev Biol. 2023; 11:1181040.
  
  
    PMID: 37397246
    
          PMC: 10309041.
    
          DOI: 10.3389/fcell.2023.1181040.
      
 
                                          
                                                          
  All roads lead to cure: Diversity of oligonucleotides in DM1 therapy.
  
    Fiszer A
    
    
    Mol Ther Nucleic Acids. 2023; 32:898-899.
  
  
    PMID: 37287495
    
          PMC: 10242478.
    
          DOI: 10.1016/j.omtn.2023.05.012.
      
 
                                          
                                                          
  Block or degrade? Balancing on- and off-target effects of antisense strategies against transcripts with expanded triplet repeats in DM1.
  
    El Boujnouni N, van der Bent M, Willemse M, t Hoen P, Brock R, Wansink D
    
    
    Mol Ther Nucleic Acids. 2023; 32:622-636.
  
  
    PMID: 37200862
    
          PMC: 10185704.
    
          DOI: 10.1016/j.omtn.2023.04.010.
      
 
                                          
                                                          
  Correction of Clcn1 alternative splicing reverses muscle fiber type transition in mice with myotonic dystrophy.
  
    Hu N, Kim E, Antoury L, Wheeler T
    
    
    Nat Commun. 2023; 14(1):1956.
  
  
    PMID: 37029100
    
          PMC: 10082032.
    
          DOI: 10.1038/s41467-023-37619-1.
      
 
                                          
                                                          
  Vorinostat Improves Myotonic Dystrophy Type 1 Splicing Abnormalities in DM1 Muscle Cell Lines and Skeletal Muscle from a DM1 Mouse Model.
  
    Neault N, Ravel-Chapuis A, Baird S, Lunde J, Poirier M, Staykov E
    
    
    Int J Mol Sci. 2023; 24(4).
  
  
    PMID: 36835205
    
          PMC: 9964082.
    
          DOI: 10.3390/ijms24043794.
      
 
                                          
                                                          
  Pluripotent Stem Cells in Disease Modeling and Drug Discovery for Myotonic Dystrophy Type 1.
  
    Berenger-Currias N, Martinat C, Baghdoyan S
    
    
    Cells. 2023; 12(4).
  
  
    PMID: 36831237
    
          PMC: 9954118.
    
          DOI: 10.3390/cells12040571.
      
 
                                          
                                                          
  Application of Antisense Conjugates for the Treatment of Myotonic Dystrophy Type 1.
  
    Stoodley J, Vallejo-Bedia F, Seone-Miraz D, Debasa-Mouce M, Wood M, Varela M
    
    
    Int J Mol Sci. 2023; 24(3).
  
  
    PMID: 36769018
    
          PMC: 9916419.
    
          DOI: 10.3390/ijms24032697.
      
 
                                          
                                                          
  RNAi in cell nuclei: potential for a new layer of biological regulation and a new strategy for therapeutic discovery.
  
    Johnson K, Corey D
    
    
    RNA. 2023; 29(4):415-422.
  
  
    PMID: 36657971
    
          PMC: 10019369.
    
          DOI: 10.1261/rna.079500.122.
      
 
                                          
                                                          
  Establishment of quantitative and consistent in vitro skeletal muscle pathological models of myotonic dystrophy type 1 using patient-derived iPSCs.
  
    Kawada R, Jonouchi T, Kagita A, Sato M, Hotta A, Sakurai H
    
    
    Sci Rep. 2023; 13(1):94.
  
  
    PMID: 36631509
    
          PMC: 9834395.
    
          DOI: 10.1038/s41598-022-26614-z.
      
 
                                          
                                                          
  Sustainable recovery of MBNL activity in autoregulatory feedback loop in myotonic dystrophy.
  
    Rogalska Z, Sobczak K
    
    
    Mol Ther Nucleic Acids. 2022; 30:438-448.
  
  
    PMID: 36420218
    
          PMC: 9672890.
    
          DOI: 10.1016/j.omtn.2022.10.023.
      
 
                                          
                                                          
  Peptide-Conjugated PMOs for the Treatment of Myotonic Dystrophy.
  
    Stoodley J, Miraz D, Jad Y, Fischer M, Wood M, Varela M
    
    
    Methods Mol Biol. 2022; 2587:209-237.
  
  
    PMID: 36401033
    
    
          DOI: 10.1007/978-1-0716-2772-3_13.
      
 
                                          
                                                          
  Recent Progress and Challenges in the Development of Antisense Therapies for Myotonic Dystrophy Type 1.
  
    De Serres-Berard T, Ait Benichou S, Jauvin D, Boutjdir M, Puymirat J, Chahine M
    
    
    Int J Mol Sci. 2022; 23(21).
  
  
    PMID: 36362145
    
          PMC: 9657934.
    
          DOI: 10.3390/ijms232113359.
      
 
                                          
                                                          
  Benefits of aerobic exercise in myotonic dystrophy type 1.
  
    MacKenzie S, Hamel J, Thornton C
    
    
    J Clin Invest. 2022; 132(10).
  
  
    PMID: 35575095
    
          PMC: 9106338.
    
          DOI: 10.1172/JCI160229.
      
 
                                          
                                                          
  Mechanistic and Therapeutic Insights into Ataxic Disorders with Pentanucleotide Expansions.
  
    Zhang N, Ashizawa T
    
    
    Cells. 2022; 11(9).
  
  
    PMID: 35563872
    
          PMC: 9099484.
    
          DOI: 10.3390/cells11091567.